Luseogliflozin significantly reduced epicardial fat volume from a median of 117 cm3 at baseline to 111 cm3 at 12 weeks in Japanese patients with type 2 diabetes.
Does luseogliflozin reduce epicardial fat volume in overweight/obese patients with type 2 diabetes?
Luseogliflozin significantly reduces epicardial fat volume and body weight in Japanese patients with type 2 diabetes, though it also leads to a reduction in skeletal muscle mass.
Absolute Event Rate: 111% vs 117%
p-value: p=0.048
Abstract Background Accumulation of epicardial fat (EF) is associated with increased cardio-metabolic risks and coronary events, independently of traditional cardiovascular risk factors. Therefore, the reduction of EF volume (EFV) may be associated with reduced cardio-metabolic risks and future cardiovascular events. Sodium-glucose co-transporter-2 (SGLT2) inhibitors reduce body fat including visceral fat and cardiovascular events in patients with type 2 diabetes. However, it has still been unknown whether SGLT2 inhibitors can reduce EFV. Methods Type 2 diabetic patients with HbA1c 6.5–9.0% and body mass index (BMI, kg/m 2 ) ≥25.0 were enrolled in this single arm pilot study. Participants were administered luseogliflozin 2.5 mg daily and the dosage was tolerated to be increased up to 5.0 mg daily. EFV median (interquartile range), cm 3 was measured by magnetic resonance imaging. Primary endpoint was the decrease in EFV at 12 weeks. Visceral fat area (VFA, cm 2 ) and liver attenuation index (LAI) measured by the abdominal computed tomography, and skeletal muscle index (SMI) and body fat (%) measured by the whole body dual-energy X-ray absorptiometry were also determined at baseline and at 12 weeks. Results Nineteen patients (mean age: 55 ± 12 years; 26% female) completed this study. Luseogliflozin treatment significantly reduced EFV at 12 weeks 117 (96–136) to 111 (88–134), p = 0.048. The body weight, BMI, systolic and diastolic blood pressure, HbA1c, fasting plasma glucose, insulin, homeostasis model assessment-insulin resistance (HOMA-IR), triglycerides, SMI, and body fat were significantly reduced by luseogliflozin at 12 weeks. The reduction of EFV was significantly correlated with the reduction of C-reactive protein (r = 0.493, p = 0.019). Neither VFA nor LAI were significantly reduced by the luseogliflozin treatment. No severe adverse events were observed. Conclusions Our data suggest that luseogliflozin could reduce the EFV in parallel with the improvement of systemic micro-inflammation and the reduction of body weight in Japanese patients with type 2 diabetes. The reduction of muscle mass after the administration of SGLT2 inhibitors may require a particular attention. Trial registration umin.ac.jp, UMIN000019072
Bouchi et al. (2017) studied Type 2 diabetes (n=19). Luseogliflozin vs. Baseline was evaluated on Decrease in epicardial fat volume (EFV) at 12 weeks (p=0.048). Luseogliflozin significantly reduced epicardial fat volume from a median of 117 cm3 at baseline to 111 cm3 at 12 weeks in Japanese patients with type 2 diabetes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: